-transparent.png){kind=logo}
Several biological response modifiers (BRMs) were demonstrated to increase myelopoiesis and effector cell responses (M phi and natural killer cell activity) in vivo. The increased myelopoiesis was reflected by an increase in bone marrow cellularity and granulocyte-M phi colony-forming cells (GM-CFU-C). The increase in myelopoiesis appeared to be related to a concomitant increase in colony-stimulated factor (CSF) production and secretion by M phi and bone marrow cells. CSF induction by BRMs increased myelopoiesis and counteracted the myelosuppressive and immunosuppressive effects of cyclophosphamide. CSF induced in vivo by BRMs attained high titers and were maintained over a longer period than exogenously injected CSF, which was rapidly cleared from serum.
M A Chirigos, and
E Schlick, and
W Budzynski
August 1989,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
M A Chirigos, and
E Schlick, and
W Budzynski
January 1994,
Cancer chemotherapy and biological response modifiers,
M A Chirigos, and
E Schlick, and
W Budzynski
May 1983,
Journal of the National Cancer Institute,
M A Chirigos, and
E Schlick, and
W Budzynski
January 1996,
Cancer chemotherapy and biological response modifiers,
M A Chirigos, and
E Schlick, and
W Budzynski
June 1986,
Seminars in oncology,
M A Chirigos, and
E Schlick, and
W Budzynski
January 1995,
European journal of cancer (Oxford, England : 1990),
M A Chirigos, and
E Schlick, and
W Budzynski
April 1995,
Lung cancer (Amsterdam, Netherlands),
M A Chirigos, and
E Schlick, and
W Budzynski
January 1999,
Cancer chemotherapy and biological response modifiers,
M A Chirigos, and
E Schlick, and
W Budzynski
January 1992,
Cancer chemotherapy and biological response modifiers,
M A Chirigos, and
E Schlick, and
W Budzynski
January 1993,
Cancer chemotherapy and biological response modifiers,
